or Try an Advanced Search...

    Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 21.94 1.29% 0.28
    SNDX closed up 1.29 percent on Wednesday, May 15, 2024, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average.
    Earnings due: May 16
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Flat
    Historical SNDX trend table...
    Date Alert Name Type % Chg
    50 DMA Resistance Bearish 0.00%
    180 Bearish Setup Bearish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    Gapped Up Strength 0.00%
    Crossed Above 20 DMA Bullish 1.29%
    Gapped Up Strength 1.29%
    Fell Below 20 DMA Bearish 4.63%
    MACD Bearish Centerline Cross Bearish 4.63%
    Outside Day Range Expansion 4.63%
    Gapped Up Strength 4.63%
    Older End-of-Day Signals for SNDX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 12 hours ago
    Possible NR7 about 13 hours ago
    10 DMA Resistance about 17 hours ago
    50 DMA Resistance about 17 hours ago
    Rose Above 50 DMA about 17 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    SNDX Chart by TradingView
    Basic chart:

    Profile

    Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Treatment Of Breast Cancer Cancer Cell Lung Cancer Cancer Therapies Hematological Malignancies Pyridines National Cancer Institute Benzamides Histone Deacetylase Inhibitor

    Is SNDX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 15 Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
    May 12 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript
    May 9 Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
    May 9 Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
    May 8 Syndax Pharmaceuticals, Inc. (SNDX) Q1 2024 Earnings Call Transcript
    May 8 Syndax Pharmaceuticals GAAP EPS of -$0.85 beats by $0.12
    May 8 Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
    May 7 Syndax Pharmaceuticals Q1 2024 Earnings Preview
    May 1 Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
    Apr 10 Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
    See more SNDX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 25.34
    52 Week Low 11.23
    Average Volume 1,055,385
    200-Day Moving Average 19.11
    50-Day Moving Average 22.29
    20-Day Moving Average 21.51
    10-Day Moving Average 22.03
    Average True Range 0.93
    RSI (14) 50.74
    ADX 13.57
    +DI 24.07
    -DI 21.02
    Chandelier Exit (Long, 3 ATRs) 20.41
    Chandelier Exit (Short, 3 ATRs) 22.93
    Upper Bollinger Bands 22.92
    Lower Bollinger Band 20.11
    Percent B (%b) 0.65
    BandWidth 13.05
    MACD Line -0.05
    MACD Signal Line -0.10
    MACD Histogram 0.0444
    Fundamentals Value
    Market Cap 1.86 Billion
    Num Shares 84.8 Million
    EPS -2.59
    Price-to-Earnings (P/E) Ratio -8.47
    Price-to-Sales 12.67
    Price-to-Book 5.22
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.93
    Resistance 3 (R3) 23.00 22.75 22.77
    Resistance 2 (R2) 22.75 22.49 22.71 22.71
    Resistance 1 (R1) 22.34 22.34 22.22 22.27 22.65
    Pivot Point 22.09 22.09 22.02 22.05 22.09
    Support 1 (S1) 21.68 21.83 21.56 21.61 21.23
    Support 2 (S2) 21.43 21.68 21.39 21.17
    Support 3 (S3) 21.02 21.43 21.12
    Support 4 (S4) 20.95